Treatment for restless legs syndrome
Wilt TJ, MacDonald R, Ouellette J, Tacklind J, Khawaja I, Rutks I, Butler M, Fink HA
Record ID 32013000765
English
Authors' objectives:
To review the comparative effectiveness, efficacy, and safety of pharmacologic and nonpharmacologic treatments for RLS.
Authors' recommendations:
Compared to placebo, dopamine agonists and alpha-2-delta ligands reduce RLS symptoms and improve patient-reported sleep outcomes and disease-specific quality of life. Adverse effects of pharmacologic therapies and long-term treatment withdrawals due to adverse effects or lack of efficacy are common. Long-term effectiveness as well as applicability for adults with milder or less frequent RLS symptoms, individuals with secondary RLS, and children is unknown.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://effectivehealthcare.ahrq.gov/ehc/products/334/1327/CER86_RestlessLegsSyndrome_FinalReport_20121119.pdf
URL for additional information:
http://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=1327
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.